Reactive PEGs,Block Copolymers,Fatty Acid Chain For Anti-diabetic Drug

Service

PEG Chemistry

· PEGylation and conjugation chemistry · Characterization of proteins Preliminary Phase 1. Feasibility study. 2. Screening study to optimize pegylation conditions. 3. Pegylation product separation and purification. 4. Pegylation product cha...
Find Out More
Analytical Chemistry

· Compounds, analysis and purification · PEG impurity profiling
Find Out More
Advanced Drug Delivery Systems (DDS)

Block copolymers and proof-of-concept for uses in DDS
Find Out More
Synthetic Organic Chemistry

· Multi-step synthesis skills (10~15 Steps), Heterocyclic compounds, Choral chemistry
Find Out More

Collaboration & Partner

SINOPEG's vision is be an science company, providing innovative materi-als and technology to partner with our customers on current treatment improvement and new therapeutics development for improved patient treatment quality and better human health.

Find Out More

Latest News

New Product Release: Sinopeg's GalNAc-PEG Lipid Now Available

In Vivo Gene Editing Therapies Offer Root-Cause Treatment for Genetic Diseases, but Efficient and Precise Liver-Targeted Delivery Remains a Critical Hurdle for Clinical Translation. Lipid Nanoparticles (LNPs), as the Mainstream Non-Viral Vector, Have...
From Structure to Functional Groups: Sinopeg Builds a Three-Dimensional PEG Derivative Product System

In the biopharmaceutical field, PEGylation technology continues to attract significant industry attention as a key means of improving drug performance. Sinopeg has deep expertise in the PEG derivative sector and is committed to providing pharmaceutic...
Breaking the Bottleneck of mRNA Pulmonary Delivery! SynTar Lipid Nanoparticles Enable a Novel Strategy for Targeted Lung Delivery

In recent years, mRNA technology has demonstrated broad application prospects in vaccine development, protein replacement therapy, and tumor immunotherapy, owing to its flexible sequence design and high expression efficiency. However, overcoming the ...

SINOPEG is a dynamic science company dedicated to drug delivery systems (DDS). As a leading company in polyethylene glycol derivatives (PEGs), we are also specialized in the R&D of long acting biopharmaceuticals, developing and manufacturing of block copolymers, lipids for drug delivery, medical devices, bio-engineering, and other broad uses.

About Us

SINOPEG is dedicated to drug delivery systems and related medical device business, focusing on the research, development, production and sales of high-end drug delivery carriers/auxiliary materials/APIs, medical materials, including but not limited to polyethylene glycol derivatives, lipid products, blood sugar control drug modifiers, block copolymers, ADC/ProTAC linkers, biodegradable polymers, exosomes, viral-like particles, as well as providing CDMO and solution services. These products are widely used in long-acting protein/peptide drugs, mRNA vaccines, small nucleic acid drugs, blood sugar control drugs, macromolecular micelle drugs...

Find Out More

Our Vision
SINOPEG’s vision is to be an science company, providing innovative materials and technology to partner with our customers
Our Mission
SINOPEG partners with our customers and collaborators to create value through:Provide innovative products to enable technolog
Our Advantage
SINOPEG has 24+ patents on PEG Derivatives and Pegylated Drugs ISO-9001 and ISO-13485 certified.
Customization
SINOPEG is able to customize a wide range of PEG products from mg to kg, and our products can meet the specific requirements of customers